Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, contributing to approximately 95% of all cases,1,2and is the most aggressive and lethal cancer out of the 60 most common types or organ cancers worldwide.3 More than 90% of PDACs contain mutations in KRAS, so it is thought to be an initiating event in malignant transformation in these cancers.
The mutated KRAS pathway leads to the deregulation of glucose, glutamine, and nucleic acid metabolism, allowing for the quick and uncontrolled proliferation of PDAC cells. Read more . . .